This study aimed to evaluate the prognostic impact of muscle volume changes during atezolizumab‐bevacizumab (AB) combination therapy (AB therapy) for unresectable hepatocellular carcinoma (u‐HCC). Additionally, we evaluated whether changes in… Click to show full abstract
This study aimed to evaluate the prognostic impact of muscle volume changes during atezolizumab‐bevacizumab (AB) combination therapy (AB therapy) for unresectable hepatocellular carcinoma (u‐HCC). Additionally, we evaluated whether changes in muscle volume relate to prognosis based on treatment response.
Keywords:
volume changes;
therapy;
impact muscle;
muscle volume;
atezolizumab bevacizumab;
volume
Journal Title: Hepatology Research
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Hepatology Research
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!